{
    "id": 25069,
    "fullName": "ESR1 - YAP1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ESR1-YAP1 results from the fusion of ESR1 and YAP1, which leads to estradiol-independent growth in cell culture, estradiol-independent enhanced gene expression, and increased cell motility (PMID: 24055055, PMID: 30089255). ESR1-YAP1 has been identified in estrogen-receptor positive breast cancer (PMID: 30089255).",
            "references": [
                {
                    "id": 1938,
                    "pubMedId": 24055055,
                    "title": "Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24055055"
                },
                {
                    "id": 12690,
                    "pubMedId": 30089255,
                    "title": "Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30089255"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "ESR1 - YAP1",
    "createDate": "08/02/2016",
    "updateDate": "10/31/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 10413,
                "geneSymbol": "YAP1",
                "terms": [
                    "YAP1",
                    "COB1",
                    "YAP",
                    "YAP2",
                    "YAP65",
                    "YKI"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9543,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft model of breast cancer harboring ESR1-YAP1 demonstrated resistance to treatment with Falsodex (fulvestrant), replicating the endocrine therapy resistance seen in the patient (PMID: 27765850).",
            "molecularProfile": {
                "id": 25835,
                "profileName": "ESR1 - YAP1"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7557,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells over expressing ESR1 - YAP1 were insensitive to Falsodex (fulvestrant) induced growth inhibition in culture (PMID: 24055055).",
            "molecularProfile": {
                "id": 25835,
                "profileName": "ESR1 - YAP1"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1938,
                    "pubMedId": 24055055,
                    "title": "Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24055055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9545,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Falsodex (fulvestrant) and SAR405838 (MI-77301) inhibited tumor growth in an endocrine-resistant patient-derived xenograft (PDX) model of breast cancer harboring ESR1-YAP1 and wild-type TP53, and had an increased effect on tumor growth delay following treatment cessation compared to SAR405838 (MI-77301) alone (PMID: 27765850).",
            "molecularProfile": {
                "id": 26890,
                "profileName": "ESR1 - YAP1 TP53 wild-type"
            },
            "therapy": {
                "id": 5068,
                "therapyName": "Fulvestrant + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15144,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Ibrance (palbociclib) resulted in growth inhibition of RB1-positive, estrogen-receptor positive breast cancer cells expressing ESR1-YAP1 in culture and inhibition of tumor growth in a RB1-positive, estrogen-receptor positive breast cancer patient-derived xenograft (PDX) model harboring ESR1-YAP1, which demonstrated reduced phosphorylation of Rb1 and decreased Ki67 levels (PMID: 30089255).",
            "molecularProfile": {
                "id": 30795,
                "profileName": "ESR1 - YAP1 RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12690,
                    "pubMedId": 30089255,
                    "title": "Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30089255"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25835,
            "profileName": "ESR1 - YAP1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26890,
            "profileName": "ESR1 - YAP1 TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30795,
            "profileName": "ESR1 - YAP1 RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}